首頁 > 市場調查報告書 > 製藥

癌症

癌胚抗原 (CEA) 市場規模、佔有率和成長分析（按類型、性別、產品類型、檢測方法、最終用戶和地區分類）—2026-2033 年產業預測

市場調查報告書

商品編碼

1900692

癌胚抗原 (CEA) 市場規模、佔有率和成長分析（按類型、性別、產品類型、檢測方法、最終用戶和地區分類）—2026-2033 年產業預測

Carcinoembryonic Antigen Market Size, Share, and Growth Analysis, By Type (Colorectal Cancer, Pancreatic Cancer), By Gender (Male, Female), By Product, By Test, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月16日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，癌胚抗原 (CEA) 市場規模將達到 27.2 億美元，到 2025 年將達到 28.6 億美元，到 2033 年將達到 41.6 億美元，在預測期（2026-2033 年）內複合年成長率為 4.8%。

癌胚抗原 (CEA) 市場目前正經歷顯著成長，這主要得益於各種癌症（尤其是結直腸癌）發病率的上升，而大腸直腸癌正是 CEA 檢測的主要應用領域。人們對癌症早期檢測和後續觀察的日益關注，導致對可靠腫瘤標記（例如 CEA）的需求不斷成長。全球癌症發生率的上升推動了對先進診斷工具的需求，CEA 已被廣泛應用於常規篩檢。此外，免疫檢測和生物標記發現等診斷技術的不斷進步，正在提高 CEA 檢測的準確性和效率。然而，成本方面的挑戰依然存在，尤其是在醫療預算有限的地區，這可能會限制新興經濟體的市場擴張。

癌胚抗原市場促進因素

包括大腸直腸癌在內的多種癌症發生率不斷上升，顯著增加了對可靠腫瘤標記（例如癌胚抗原 (CEA)）的需求。 CEA 檢測能夠早期發現癌症並監測其進展，這在患者管理和治療效果中發揮著至關重要的作用。醫護人員和患者都在尋求更精準的診斷工具以改善早期檢測，這推動了 CEA 在臨床實踐中日益重要的地位和廣泛的應用。人們對 CEA 在腫瘤學領域價值的認知不斷提高，是推動該市場擴張的主要因素。

限制癌胚抗原（CEA）市場的因素

癌胚抗原 (CEA) 市場面臨的主要限制因素在於 CEA 檢測相關的經濟障礙。價格承受能力是亟待解決的問題，尤其是在醫療資源有限的地區，這影響了該檢測的廣泛應用。此外，市場上還存在其他診斷方法的競爭，例如先進的影像技術和液態生物檢體，這可能會導致人們的關注點和資源從 CEA 檢測轉移開來。這些因素共同構成了 CEA 市場成長和滲透的挑戰性環境，限制了其在醫療診斷領域的整體潛力。

癌胚抗原（CEA）市場趨勢

由於先進技術與調查方法的融合日益增強，癌胚抗原 (CEA) 市場呈現顯著的成長趨勢。這包括診斷技術的改進，例如創新免疫檢測的開發和生物標記發現的進展，這些都顯著提高了 CEA 檢測的準確性和性能。此外，CEA 的應用範圍正在從傳統的癌症診斷擴展到其他領域，探索其在各種治療領域和個人化醫療中的應用潛力。技術和應用的拓展，以及應用範圍的擴大，正在推動癌症診斷市場的成長，並提升整體標準。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

F. Hoffmann-La Roche Ltd.（Switzerland）
Thermo Fisher Scientific Inc.（USA）
Quest Diagnostics Incorporated（USA）
Abbott Laboratories（USA）
Merck KGaA（Germany）
Laboratory Corporation of America Holdings（USA）
Siemens Healthineers AG（Germany）
Bio-Rad Laboratories, Inc.（USA）
Creative Diagnostics（USA）
Aviva Systems Biology Corporation（USA）
Omega Diagnostics Ltd.（UK）
RayBiotech, Inc.（USA）
Boster Biological Technology（USA）
Diazyme Laboratories Inc.（USA）
GenScript Corporation（USA）
Lee BioSolutions（USA）
Danaher Corporation（USA）
Novartis AG（Switzerland）
Agilent Technologies, Inc.（USA）

結論與建議

簡介目錄

Product Code: SQMIG35H2233

Carcinoembryonic Antigen Market size was valued at USD 2.72 Billion in 2024 and is poised to grow from USD 2.86 Billion in 2025 to USD 4.16 Billion by 2033, growing at a CAGR of 4.8% during the forecast period (2026-2033).

The Carcinoembryonic Antigen (CEA) market is currently experiencing significant growth, driven by the rising incidence of various cancers, particularly colorectal cancer, which is a primary application for CEA testing. With a growing focus on early cancer detection and monitoring, the demand for reliable tumor markers like CEA is on the rise. The increasing global prevalence of cancers has heightened the need for advanced diagnostic tools where CEA is prominently utilized in routine screenings. Furthermore, ongoing advancements in diagnostic technologies, such as immunoassays and biomarker discovery, are enhancing the precision and efficiency of CEA testing. However, cost-related challenges persist, particularly in regions with constrained healthcare budgets, potentially limiting market expansion in emerging economies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Carcinoembryonic Antigen market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Carcinoembryonic Antigen Market Segments Analysis

Global Carcinoembryonic Antigen Market is segmented by Type, Gender, Product, Test, End User and region. Based on Type, the market is segmented into Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Breast Cancer, Thyroid Cancer and Others. Based on Gender, the market is segmented into Male and Female. Based on Product, the market is segmented into CD66a, CD66b, CD66c, CD66d, CD66e and CD66f. Based on Test, the market is segmented into Molecular Test and Serology Test. Based on End User, the market is segmented into Hospitals & Clinics, Research Institutes, Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Carcinoembryonic Antigen Market

The increasing prevalence of various cancers, particularly colorectal cancer, has significantly heightened the demand for reliable tumor markers such as Carcinoembryonic Antigen (CEA). The ability to detect cancer early and monitor its progression through CEA testing plays a vital role in patient management and treatment outcomes. As healthcare professionals and patients alike seek more accurate diagnostic tools to improve early detection, the importance of CEA in clinical settings has intensified, driving its widespread adoption. This growing recognition of the value of CEA in oncology is a key factor contributing to the expansion of this market.

Restraints in the Carcinoembryonic Antigen Market

A significant limitation in the Carcinoembryonic Antigen (CEA) market stems from the financial barriers associated with CEA testing. The issue of affordability is particularly pressing in regions with limited healthcare funding, which impacts widespread access and adoption of these tests. Additionally, the market faces competition from alternative diagnostic methods, including advanced imaging techniques and liquid biopsies, which may draw attention and resources away from a concentrated focus on CEA testing. These factors collectively contribute to a challenging environment for the growth and penetration of the CEA market, limiting its overall potential in healthcare diagnostics.

Market Trends of the Carcinoembryonic Antigen Market

The Carcinoembryonic Antigen (CEA) market is witnessing a notable trend driven by the rising integration of advanced technologies in testing methodologies. This includes enhancements in diagnostic technologies, such as the development of innovative immunoassays and advancements in biomarker discovery, which significantly elevate the precision and performance of CEA tests. Furthermore, there is an expanding scope of CEA applications beyond traditional cancer diagnostics, exploring its potential in various therapeutic areas and personalized medicine. This convergence of technology and expanded utility is fueling growth and elevating the overall standards of cancer diagnostics within the market.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Carcinoembryonic Antigen Market Size by Type & CAGR (2026-2033)

Market Overview
Colorectal Cancer
Pancreatic Cancer
Ovarian Cancer
Breast Cancer
Thyroid Cancer
Others

Global Carcinoembryonic Antigen Market Size by Gender & CAGR (2026-2033)

Market Overview
Male
Female

Global Carcinoembryonic Antigen Market Size by Product & CAGR (2026-2033)

Market Overview
CD66a
CD66b
CD66c
CD66d
CD66e
CD66f

Global Carcinoembryonic Antigen Market Size by Test & CAGR (2026-2033)

Market Overview
Molecular Test
Serology Test

Global Carcinoembryonic Antigen Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals & Clinics
Research Institutes
Surgical Centers
Others

Global Carcinoembryonic Antigen Market Size & CAGR (2026-2033)

North America (Type, Gender, Product, Test, End User)
- US
- Canada
Europe (Type, Gender, Product, Test, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Gender, Product, Test, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Gender, Product, Test, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Gender, Product, Test, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quest Diagnostics Incorporated (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Laboratory Corporation of America Holdings (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Creative Diagnostics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aviva Systems Biology Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Omega Diagnostics Ltd. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
RayBiotech, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boster Biological Technology (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Diazyme Laboratories Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GenScript Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lee BioSolutions (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments